Erasca (ERAS) traded higher Friday, up roughly 4% to $19.20, extending a volatile stretch for the clinical-stage oncology name. The move appears tied to a mix of catalyst-driven positioning around upcoming pipeline updates and increased speculative activity in the options market.

Erasca has guided for additional Phase 1 data for its lead program ERAS‑0015 in the first half of 2026, following early clinical activity that included partial responses across multiple tumor types and RAS mutations at low doses, with a favorable safety profile and no dose-limiting toxicities at the referenced cutoff. With the calendar now deep into 1H26, traders are increasingly treating any incremental trial update, conference appearance, or corporate deck refresh as a near-term catalyst window. (investors.erasca.com)

Separately, ERAS has recently seen unusually large call-option volume, a pattern that can amplify daily moves as market-makers hedge and short-term traders lean into momentum. While options flow alone does not confirm a fundamental change, it often coincides with event-driven setups in biotech ahead of anticipated data or company updates. (defenseworld.net)